Hutchison China MediTech Limited (HCM)

31.52 -0.62 (-1.93%) At close: 4:00PM EDT

Hutchison China MediTech Limited

Cheung Kong Center
48th Floor 2 Queen's Road
Central
Hong Kong
852 2121 8200
http://www.chi-med.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 853

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBA	Exec. Chairman	80k	N/A	1952
Mr. Christian Hogg B.Sc., M.B.A., BSc, MBA	CEO & Exec. Director	1.44M	N/A	1966
Mr. Johnny Cheng C.A., BEc, CA	CFO & Exec. Director	769.68k	N/A	1967
Dr. Wei-Guo Su B.Sc., Ph.D.	Chief Scientific Officer, Exec. VP & Exec. Director	1.13M	N/A	1957
Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE)	Company Sec. & Non-Exec. Director	70k	N/A	1952

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

Corporate governance

Hutchison China MediTech Limited’s ISS governance QualityScore as of 8 December 2019 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.